Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Dose Ranging Study to Assess the Safety and Distribution of Single or Multiple Doses of VB-111 in Patients With Advanced Metastatic Cancer

NCT00559117 is registered in ClinicalTrials.gov with Vascular Biogenics Ltd. operating as VBL Therapeutics as lead sponsor.

NCT NCT00559117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00559117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Dose Ranging Study to Assess the Safety and Distribution of Single or Multiple Doses of VB-111 in Patients With Advanced Metastatic Cancer
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase
Phase 1
Overall status
Unknown status
Start date
November 30, 2007
Completion date
June 30, 2015
Enrollment
48 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced and/or metastatic solid organ cancer